> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AstraZeneca Positive Results for Imfinzi in Lung Cancer
- URL: https://www.fdaweb.com/astrazeneca-positive-results-for-imfinzi-in-lung-cancer/
- Published: 2019-10-29T12:00:00.000Z
- Updated: 2026-09-15T01:59:40.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145363

AstraZeneca has announced positive progression-free survival (PFS) results from the Phase 3 POSEIDON trial in previously-untreated Stage IV (metastatic) non-small cell lung cancer (NSCLC) for Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody, when added to chemotherapy. “The trial met a primary endpoint by showing a statistically significant and clinically meaningful improvement in the final PFS analysis in patients treated with the combination of Imfinzi and a broad choice of five standard-of-care platinum-based chemotherapy options vs. chemotherapy alone,” the company says. The triple combination also showed a statistically significant and clinically meaningful PFS improvement vs. chemotherapy alone as a key secondary endpoint.

AstraZeneca says that the POSEIDON trial will continue to assess the primary endpoint of overall survival with data expected next year. AstraZeneca says it will submit the results for presentation at an upcoming medical meeting and plans to make regulator submissions seeking related approvals. Imfinzi is also being studied tested in Stage IV NSCLC as monotherapy in the Phase III PEARL trial, and in earlier stages of disease as part of the company’s Immuno-Oncology lung cancer program.

Imfinzi is approved in the curative-intent setting of unresectable, Stage III NSCLC after chemoradiation therapy in 53 countries, including the U.S.